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1 These authors contributed equally to this work.MIF is a chemokine-like inﬂammatory mediator that triggers leukocyte recruitment by binding to
CXCR2 and CXCR4. MIF also interacts with CD74/invariant chain, a single-pass membrane-receptor.
We identiﬁed complexes between CD74 and CXCR2 with a role in leukocyte recruitment. It is
unknown whether CD74 also binds to CXCR4. We demonstrate that CD74/CXCR4 complexes formed
when CD74 was expressed with CXCR4 in HEK293 cells. Expression of CD74-variants lacking an ER-
retention signal showed CD74/CXCR4 complexes at the cell surface. Importantly, endogenous CD74/
CXCR4 complexes were isolated by co-immunoprecipitation from monocytes. Finally, MIF-stimu-
lated CD74-dependent AKT activation was blocked by anti-CXCR4 and anti-CD74 antibodies and
AMD3100, whereas CXCL12-stimulated AKT activation was not reduced by anti-CD74. Thus, CD74
forms functional complexes with CXCR4 that mediate MIF-speciﬁc signaling.
Structured summary:
MINT-7234512, MINT-7234528: CD74 (uniprotkb:P04233) physically interacts (MI:0915) with CXCR4
(uniprotkb:P61073) by anti tag coimmunoprecipitation (MI:0007)
MINT-7234542: CD74 (uniprotkb:P04233) and CXCR4 (uniprotkb:P61073) physically interact (MI:0915)
by anti bait coimmunoprecipitation (MI:0006)
MINT-7234499: CXCR4 (uniprotkb:P61073) and CD74 (uniprotkb:P04233) colocalize (MI:0403) by ﬂuores-
cence microscopy (MI:0416)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction lance and inﬂammation. The structural classiﬁcation of chemo-Macrophage migration inhibitory factor (MIF) is a structurally
unique 12.5 kDa cytokine that is a critical mediator of acute and
chronic inﬂammatory diseases such as septic shock, Crohn’s dis-
ease, rheumatoid arthritis, and atherosclerosis, as well as cancer
[1–4]. Contrary to its historic name, MIF has been recognized to
exhibit chemokine-like properties [5,6] and was identiﬁed as a
non-cognate ligand of the chemokine receptors CXCR2 and CXCR4
[5].
Chemokines are chemotactic cytokines that orchestrate the
activation and recruitment of leukocytes during immune surveil-chemical Societies. Published by E
, CXC-type chemokine recep-
rotein-coupled receptor; Ii,
factor; SDF-1a, stromal cell-
agen).kines and their G protein–coupled receptors (GPCRs) has been
well deﬁned. Over 50 chemokines bind to some 20 receptors,
which constitutes a redundancy with respect to ligand action [7–
10]. CXCR2 is the prototypic receptor for ELR+ chemokines such
as CXCL8 (interleukin-8, IL-8) or CXCL1/GRO-a. Pathophysiological
processes ranging from inﬂammatory leukocyte recruitment to
cancer cell migration and angiogenesis are mediated by CXCL8/
CXCR2 [7]. CXCR4 has been considered the sole receptor for the
chemokine CXCL12 (stromal cell-derived factor-1a, SDF-1a),
although CXCR7 has recently been suggested as an alternative
receptor for CXCL12 [11]. The dogma of a monogamous relation-
ship between CXCR4 and CXCL12 also has been challenged by
the observations that HIV gp120 and MIF bind to CXCR4 [4,5,12].
The CXCL12/CXCR4 axis is involved in various homeostatic and
inﬂammatory cell migration processes, including inﬂammatory
and atherogenic T cell recruitment, stem cell homing, and cancer
cell metastasis [7,13].
In spite of architectural similarities, MIF does not belong to the
canonical CC, CXC, CX3C, or C sub-families of chemokines and haslsevier B.V. All rights reserved.
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[4,5,14]. Binding of MIF to CXCR2 is dependent on a pseudo(E)LR
motif that is reminiscent of the ELR motif [15]. Through its dual
interaction with CXCR2 and CXCR4, MIF uniquely triggers both
monocyte and T cell arrest on atherogenic endothelium, promotes
leukocyte transmigration, and increases the formation and pro-
gression of atherosclerotic plaques [4,5].
MIF also interacts with CD74, a single-pass type II membrane
protein, also known as MHC class II invariant chain (Ii) [16]. Ii asso-
ciates with MHC class II molecules during endoplasmic reticulum
(ER)-endolysosomal trafﬁc and functions as class II chaperone to
control antigenic peptide loading. CD74 is the membrane form of
Ii, which in smaller percentage trafﬁcs to the plasma membrane,
presumably after modiﬁcation by chondroitin sulfate. Surface
CD74 is expressed on class II-positive cells but upon inﬂammatory
stimulation, can be detected at the plasma membrane of class II-
negative cells, including stromal and epithelial cell types [17,18].
There is ample evidence that surface interaction of MIF with
CD74 leads to activation of ERK1/2-MAPK and AKT/PI3K signaling.
CD74 also is important for the regulation of B cell survival by MIF
[19]. MIF-triggered ERK1/2 signaling requires the recruitment of
CD44 and a non-receptor tyrosine kinase [16,20]. We recently
identiﬁed receptor complexes between CD74 and CXCR2. The pre-
cise molecular details of this interaction are unclear, but it has be-
come evident that CD74/CXCR2 complexes play an important role
in MIF-driven atherogenic leukocyte recruitment [5]. Binding of
CD74 to CXCR2 exempliﬁes heteromeric receptor complex forma-
tion between a GPCR and a single-pass transmembrane protein
and may be associated with cross-talk between receptor tyrosine
kinase (RTK) complexes and GPCR [4,5].
We examined whether CD74 interacts with CXCR4, the second
chemokine receptor utilized by MIF. Applying ﬂow cytometry
and ﬂuorescence microscopy, we established that HEK293 cells
transfected with tagged fusion proteins of CD74 and CXCR2 ex-
pressed both receptors. A CD74 variant lacking the ER retention
signal that prevents surface trafﬁcking of CD74 in the absence of
class II was applied to verify interactions between CD74 and CXCR4
at the cell surface. We then investigated an interaction between
these receptors by co-immunoprecipitation (CoIP)/pull-down anal-
ysis and confocal microscopy using overexpressed receptor fusion
and endogenous proteins. A functional interplay between CD74
and CXCR4 was addressed in a MIF-triggered CD74-dependent sig-
naling assay by applying a CXCR4-speciﬁc small molecule inhibitor
and by comparing the effects of MIF and CXCL12 in the presence
versus absence of blocking anti-CD74 and anti-CXCR4 antibodies.2. Materials and methods
2.1. Plasmids, antibodies and reagents
Recombinant human MIF (rMIF) was prepared as described and
contained negligible concentrations of endotoxin (<10 pg endo-
toxin/lg MIF) [21]. AMD3100 was purchased from Sigma.
The plasmid for V5-tagged CD74, pcDNA3.1/V5-His-TOPO-
CD74, has been described [16]. pEYFP-C1-CD74 was generated by
cloning the cDNA encoding human CD74 into pEYFP-C1, wherein
the cDNA for CD74 was ampliﬁed from pcDNA3.1/V5-His-TOPO-
CD74 [16] using primers: 50-TCCGCTCGAGCGATGCACAGGAGGA-
GA-30 and 50-AGCGAATTCCGTCACATGGGGACTGGGCC-30. Un-
tagged CD74 plasmid encoding for a p33 variant of human CD74
devoid of the ER retention signal [22] and that is abundantly tar-
geted to the cell surface was termed pCD74minRTS and was a gift
of Carolus Therapeutics (San Diego, CA, USA). pEYFP-C1-CD74min-
RTS was cloned by inserting CD74minRTS into pEYFP-C1 (see
above). pECFP-N1-CXCR4 was generated by cloning human CXCR4cDNA into pECFP-N1. The CXCR4 cDNA was ampliﬁed from
pcDNA3.1-CXCR4(HA)3 (Missouri S&T cDNA Resource Center)
using primers: 50-TCCGCTCGAGCCATGTACCCATACGAT-30 and 50-
AGCGAATTCCGCTGGAGTGAAAACTTGAAG-30. pBABEpuro was from
B. Lüscher (RWTH Aachen University) and originally obtained from
Addgene, USA.
Antibodies used were: mouse monoclonal antibody (mAb)-V5
(R960-25, Invitrogen, Karlsruhe, Germany), rat anti-HA mAb
(3F10, Roche Diagnostics, Mannheim, Germany), mouse isotype
control IgG1 (14-4714, eBioscience, San Diego, USA), human
anti-CD74 mAb (M-B741, 555538, BD Pharmingen, San Diego),
human anti-CD74 mAb (C-16, sc-5438, Santa Cruz Biotechnology),
polyclonal rabbit anti-CXCR4 (c8352, Sigma, Taufkirchen, Ger-
many), horseradish peroxidase (HRP)-conjugated anti-mouse
antibody (1858413, Pierce Biotechnology, Rockford, USA), HRP-
conjugated anti-rat antibody (NA9350, GE Healthcare/Amersham,
Freiburg, Germany) and HRP-conjugated anti-rabbit IgG
(1858415, Pierce) for CoIPs and pull-downs. Fluorescein-conju-
gated mouse anti-human CXCR4 (FAB170f, R&D Systems) and
mouse anti-human CD74 (M-B741, 555540, BD Pharmingen) were
applied for ﬂow cytometry. Anti-phospho-AKT (Ser 473-speciﬁc,
Cell Signaling, Danvers, MA, USA), anti-actin (Ab 691001, MP Bio-
medicals, Eschwege, Germany), HRP-conjugated sheep anti-
mouse IgG (GE Healthcare) and HRP-conjugated donkey anti-rab-
bit IgG (GE) were used for the AKT signaling assay. For neutraliza-
tion experiments, anti-human CXCR4 mAb (MAB171, R&D
Systems, Wiesbaden, Germany), anti-human CD74 (Ab 555612,
BD Pharmingen, Heidelberg, Germany), and an isotype IgG1 (eBio-
sciences) were used. Other reagents were of the highest grade
commercially available.2.2. Cell culture and transfections
Cell culture reagents including media, supplements and antibi-
otics were from Invitrogen (Karlsruhe, Germany). Unless stated
otherwise, cell culture experiments were performed at 37 C in a
humidiﬁed incubator with 5% CO2.
Human embryonic kidney cells (HEK293) and MonoMac6 hu-
man monocytes were purchased from the German Society for
Microorganisms and Cell Cultures (DSMZ, Braunschweig, Ger-
many). HEK293 cells were cultured in Dulbecco’s modiﬁed Eagle
medium (DMEM) supplemented with GlutamaxTM containing
4.5 g/l D-glucose and sodium pyruvate, containing 10% fetal calf
serum (FCS) and 1% penicillin/streptomycin (P/S). MonoMac6
cells were cultured in RPMI 1640 medium containing 10% FCS,
1% P/S, 1% non-essential amino acids (NEAA), 9 lg/ml human
insulin (Sanoﬁ-Aventis) and 1 mM sodium pyruvate. Jurkat T
cells were purchased from ATCC (TIB152) and were cultured in
RPMI 1640 medium containing 10% FCS and 1% P/S.
For transient transfections of HEK293, FuGENE HD transfection
reagent from Roche Diagnostics (Grenzach-Wyhlen, Germany) was
used.2.3. Flow cytometry
HEK293 transfectants, MonoMac6 and Jurkat cells were sub-
jected to ﬂow cytometry. Jurkat T cells were treated in medium
containing reduced concentrations of FCS (0.5%) for 24–48 h be-
fore ﬂow cytometric analysis. For each measurement, 200 000
cells were washed once with buffer (1 phosphate-buffered sal-
ine (PBS), pH 7.2, containing 0.5% bovine serum albumin (BSA)
and 0.1% azide). Cells were labeled with anti-CXCR4-FITC (1:3.5)
or anti-CD74-FITC (1:20). After washing and resuspension, cells
were analyzed on a FACS CantoTM (BD Bioscience, Heidelberg,
Germany).
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One day after seeding, HEK293 cells were transiently transfec-
ted with pECFP-N1-CXCR4, pEYFP-C1-CD74minRTS, and pBABEpuro,
respectively, and incubated for 24 h at 37 C and 5% CO2. Medium
was changed and cells selected by addition of puromycin (1 lg/ml,
Calbiochem, Darmstadt, Germany) for 24 h. Medium was aspi-
rated, cells detached and centrifuged at 1250 rpm for 5 min.
The supernatant was aspirated and the pellet resuspended in
DMEM medium. To one well of a 6-well-plate containing a sterile
poly-L-lysine-coated cover slip, 3 ml of the cell suspension were
added. Seeded cells were incubated for 24 h at 37 C and 5%
CO2, were washed under live-cell imaging conditions [5] and stud-
ied using an Axiovert 100 M confocal microscope (Carl Zeiss,
Oberkochen, Germany).
2.5. Coimmunoprecipitations and pull-down experiments
Fourty-eight hours after transfection with combinations of plas-
mids pcDNA3.1/V5-His-TOPO-CD74 and pcDNA3.1-CXCR4(HA)3, or
pCD74minRTS and pcDNA3.1-CXCR4(HA)3, HEK293 transfectantsd YFP-CD74minRTS CXCR4-CFP
ba
Fig. 1. Cell surface expression of the MIF receptor fusion proteins following overexpress
and CXCR4-CFP were ectopically expressed in HEK293 cells. (a) Flow cytometry histog
CXCR4-stained cells (green) is compared with that of cells stained with FITC-IgG (gr
Comparison between anti-CD74-stained cells (red) and cells stained with FITC-IgG
Fluorescence intensity of anti-CD74-stained cells (red) is compared with that of cells
potentiated cell surface expression of CD74 (compare c with b). (d) Colocalisation of CX
with an Axiovert 100M/Zeiss LSM510 confocal microscope. Arrows indicate spots of st
Arrow + asterisk indicates a spot of marked intracellular colocalisation (possibly endolys
membrane.were disrupted with CoIP buffer (50 mM Tris–HCl, pH 7.4, contain-
ing 100 mM NaCl, 15 mM EGTA, 1% Triton X-100, 1% CHAPSO,
0.02% azide, and protease inhibitor cocktail (Calbiochem, Darms-
tadt, 1:100)). After clearance of lysates, samples were incubated
for 2 h at 4 C with either anti-V5 or -HA antibodies or isotype
mouse IgG1 (negative control). Protein-G beads (NEB, Frankfurt)
were blocked with PBS, containing 1% BSA, and resuspended in
200 ll CoIP buffer. Lysates were incubated with pre-treated pro-
tein-G beads overnight at 4 C. Beads with bound immune com-
plexes were washed once with 500 ll CoIP buffer and 4 with a
1:5 dilution CoIP buffer. Beads were resuspended in sample buffer
and samples subjected to SDS-PAGE/Western blotting. Blots were
revealed with rat anti-HA (1:2000), mouse anti-V5 (1:5000), rabbit
anti-CXCR4 (1:1000), or anti-CD74 (1:500) antibodies. HRP-conju-
gated anti-mouse (1:1000) or anti-rat (1:1000) antibodies were
used as secondary antibodies. Chemiluminescence was detected
by ECL (Pierce). For corresponding pull-down controls, blots were
inversely developed with anti-V5, anti-HA, or anti-CXCR4,
respectively.
For immunoprecipitation of endogenous receptor complexes,
MonoMac6 cells were cultured in the presence of human inter-Overlay
*
c
ion. Fusion proteins HA-CXCR4, V5-CD74, CD74minRTS as well as YFP-CD74minRTS
ram of HEK293 cells expressing HA-tagged CXCR4. Fluorescence intensity of anti-
ey). (b) Flow cytometry histogram of HEK293 cells expressing V5-tagged CD74.
(grey). (c) Flow cytometry histogram of HEK293 cells expressing CD74minRTS.
stained with FITC-IgG (grey). Note: deletion of the ER retention signal in CD74
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Fig. 2. Protein complex formation of overexpressed CXCR4 and CD74 as revealed by coimmunoprecipitation. HA-CXCR4 and V5-CD74 fusion proteins or HA-CXCR4 together
with the CD74minRTS protein were ectopically expressed in HEK293 cells. (a, left) V5-CD74 was immunoprecipitated with an anti-V5 antibody and coprecipitated CXCR4
detected by anti-HA or anti-CXCR4 antibody. (a, right) Control blot developed for CD74. (b, left) Inverse setting as in (a) with immunoprecipitation performed with anti-HA
antibody and Western blot with anti-V5 antibody. (b, right) Control blot developed for CXCR4 by anti-HA or anti-CXCR4 antibody. (c, left) Setting as in (b) except that
pCD74minRTS was transfected and blots developed with an anti-CD74 antibody. (c, right) Control blot developed for CXCR4. Control immunoprecipitations were performed
with beads alone (control); input lanes indicate Western blot analysis performed on 5% of the corresponding HEK293 lysates. Molecular weight standards were
electrophoresed in the same gels (Mr). IP, immunoprecipitation; WB, Western blot. Non-speciﬁc staining of immunoglobulin heavy (IgG-HC) and light (IgG-LC) chains by the
secondary WB antibody is indicated. Please note that the anti-HA antibody is a poor WB antibody; thus input controls for CXCR4 showed a weak or no band, but were
detectable with anti-CXCR4 (lower panel in a, left and b, right).
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applied. Pull-downs of receptor complexes from the lysates ofthese cells were performed with an anti-CD74 antibody versus
IgG1 as control. For Western blot, anti-CXCR4 (1:1000) antibody
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(1:1000) as secondary antibody. CD74 pull-down controls were re-
vealed by Western blotting with anti-CD74 (1:500).
2.6. AKT signal transduction assay
For AKT activation analysis in Jurkat cells, cells were grown
inRPMI 1640 medium containing 10% FCS and medium replaced
by RPMI 1640/0.5% FCS for 24 h. Untreated Jurkat cells and
those pre-incubated with the CXCR4-speciﬁc inhibitor AMD3100
(1 lg/ml, 30 min) were incubated with rMIF (0-1250 ng/ml,
10 min). For blocking CD74 or CXCR4, cells were pre-treated with
10 lg/ml neutralizing anti-CD74 mAb or 10 lg/ml anti-CXCR4
mAb for 30 min. For control, pre-treatment with isotype IgG was
performed. Phosphorylation ratios (phospho-Ser473-AKT/actin)
were calculated by band densitometry using Aida Image Analyser
Software (Raytest Isotopen, Berlin, Germany).Mr [kDa]
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Fig. 3. Formation of endogenous CXCR4/CD74 receptor complexes in monocytes. Co-imm
cells. (a) Flow cytometry histogram showing abundant surface expression of CXCR4 in M
with that of cells stained with FITC-IgG (grey). (b) Flow cytometry analysis as in a but sta
revealed by coimmunoprecipitation. MonoMac6 lysates were subjected to immunopreci
anti-CXCR4. (d) Control blot developed for CD74. Control immunoprecipitations were
performed on 5% of MonoMac6 lysate. Molecular weight standards were electrophores
staining of immunoglobulin heavy (IgG-HC) and light (IgG-LC) chains by the secondary
40 kDa a second speciﬁc band was detected which is likely to represent a differently gly2.7. Statistical analysis
Statistical signiﬁcance between two groups of data was evalu-
ated by Student’s t-test. P values below 0.05 were considered sta-
tistically signiﬁcant.
3. Results
3.1. Colocalization and protein complex formation of CD74 and CXCR4
receptor fusion proteins
To study the interaction between CD74 and CXCR4, we applied
the following fusion proteins: (i) a V5-His-tagged p35 form of
CD74, (ii) an HA-tagged CXCR4, and (iii) CXCR4-CFP with the
CFP-tag fused C-terminally to CXCR4. A variant of CD74 lacking
the ER retention signal mediating ER retention of CD74 (CD74min-
RTS) in cells that do not express MHC class II was used as untaggedWB: CXCR4
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Fig. 4. CXCR4/CD74 receptor complex formation correlates with a functional interplay between CD74 and CXCR4. The CXCR4 inhibitor AMD3100 as well as anti-CXCR4 and
anti-CD74 antibodies block MIF-mediated AKT activation in Jurkat T cells, whereas SDF-1a-mediated AKT activation is only reduced by anti-CXCR4 but not anti-CD74. (a)
Flow cytometry histogram showing surface expression of CXCR4 in Jurkat T cells. Fluorescence intensity of anti-CXCR4-stained cells (green) is compared with that of cells
stained with a non-speciﬁc FITC-IgG (grey). (b) Flow cytometry histogram showing surface expression of CD74 in Jurkat T cells. Fluorescence intensity of anti-CD74-stained
cells (red) is compared with that of cells stained with a non-speciﬁc FITC-IgG (grey). (c) Jurkat cells pre-treated with AMD3100 (1 lg/ml, 30 min; +AMD3100) or with control
buffer were incubated with rMIF at indicated concentrations for 10 min and AKT activation measured by Western blot using a phospho-Ser473-AKT antibody. Actin staining
was performed for standardization of the blot. (d) Quantiﬁcation of the blot according to (c) (phosphorylation ratio: AKT/actin; mean of n = 2). (e) As in c except that Jurkat
cells were pre-treated with anti-CD74, anti-CXCR4 antibody or control IgG1 (10 lg/ml each, 30 min). MIF was added at a concentration of 100 ng/ml and for comparison cells
were stimulated with 100 ng/ml SDF-1a. (f) Quantiﬁcation of the blot according to (e) (phosphorylation ratio: AKT/actin; mean of n = 2).
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N-terminus of CD74 (v).Using Western blotting we ﬁrst established that CD74 and
CXCR4 fusion proteins were efﬁciently overexpressed in HEK293
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of CXCR4 (data not shown). Flow cytometry histograms conﬁrmed
expression of HA-tagged CXCR4 and demonstrated surface locali-
zation of this receptor fusion protein (Fig. 1a). However, V5-tagged
CD74 could not be detected on the surface of HEK293 cells
(Fig. 1b). It is known that only a minor portion of Ii/CD74 is tar-
geted to the surface, whereas most of it remains localized in the
ER/endolysosomal compartment. We thus ectopically expressed
the CD74minRTS variant, which proved to exhibit abundant sur-
face expression (Fig. 1c). To further conﬁrm surface expression of
CXCR4 and CD74, we applied CXCR4-CFP and YFP-CD74minRTS
in confocal ﬂuorescence microscopy studies. These experiments
veriﬁed marked surface expression of both receptor constructs
(Fig. 1d) and provided evidence that YFP-CD74 and CXCR4-CFP
co-localized in sections of the plasma membrane of the double-
transfectants. In line with the notion that CXCR4 also is rapidly
re-internalized following surface targeting [23], intracellular co-
localization between the ﬂuorescent fusion receptors was also ob-
served, especially at subcellular spots of excessive YFP-CD74
expression (Fig. 1d).
We next studied receptor complex formation of CD74 and
CXCR4 by biochemical methods. V5-tagged CD74 was pulled-
down from HEK293 lysates by anti-V5 antibody and co-precipi-
tated CXCR4 revealed by Western blotting using anti-HA or
anti-CXCR4 antibody. A strong CXCR4 band was detected under
these conditions whereas blots from pull-downs applying protein
G beads alone were devoid of CXCR4, indicating that overexpres-
sed V5-CD74 strongly bound to HA-CXCR4 in HEK293 cells
(Fig. 2a, left). Pull-down efﬁciency was conﬁrmed by anti-V5
Western blot (Fig. 2a, right). For conﬁrmation, the pull-down/
Western blot experiment was performed in reverse setting, i.e.
pull-down of CXCR4 with anti-HA and blot development with
anti-V5 antibody. This experiment yielded a speciﬁc band, again
suggesting CD74/CXCR4 complex formation, whereas the control
pull-down only showed a weak non-speciﬁc band (Fig. 2b, left).
Pull-down efﬁciency was conﬁrmed by anti-HA or anti-CXCR4
Western blot (Fig. 2b, right). To ask whether increased plasma
membrane expression of CD74 would lead to an improved
pull-down rate of CXCR4/CD74 complexes, HEK293 cells were
transfected with pCD74minRTS together with pHA-CXCR4 and
complexes pulled-down by anti-HA antibody. In fact, the band
for co-precipitated CD74 devoid of the ER retention signal was
more pronounced than that for V5-full length CD74 (compare
Fig. 2c, left with Fig. 2b, left), indicating that CXCR4/CD74 com-
plex formation is favoured at the plasma membrane. Again, pull-
down efﬁciency was conﬁrmed by anti-HA Western blot (Fig. 2c,
right).3.2. Protein complex formation of endogenously expressed CD74 and
CXCR4 receptors
To verify that CD74 and CXCR4 bind to each other, we studied
receptor complex formation of the endogenously expressed pro-
teins in human MonoMac6 monocytes. These cells endogenously
expressed substantial levels of both receptors on their surface
(Fig. 3a and b). Importantly, when lysates of MonoMac6 cells were
immunoprecipitated with anti-CD74, endogenous CXCR4 was
found to be coprecipitated as revealed by anti-CXCR4 Western blot
showing a strong band at 40 kDa which was not present in the
control CoIP (Fig. 3c). A second, apparently speciﬁc, band was seen
at 45–47 kDa and may represent a differentially glycosylated
CXCR4 species. Pull-down efﬁciency was conﬁrmed by anti-CD74
blot (Fig. 3d). Thus, portions of endogenously expressed CD74
can bind to fractions of endogenously expressed CXCR4 in
monocytes.3.3. MIF-stimulated AKT activation in T lymphocytes is dependent on
both CD74 and CXCR4
We previously demonstrated CD74-dependent AKT activation
by MIF in mouse embryonic ﬁbroblasts [24]. Here we asked
whether complex formation between CD74 and CXCR4 was accom-
panied by a functional interplay between these receptors during
MIF signaling. AKT activation in Jurkat T cells, which endogenously
express appreciable levels of both CXCR4 and CD74 on the plasma
membrane (Fig. 4a and b), was triggered by rMIF. To ask whether
MIF-stimulated AKT activation was mediated by CXCR4/CD74
complexes, CD74 was blocked with a neutralizing CD74 antibody
and CXCR4 was inhibited by AMD3100 or CXCR4 antibody. Results
were compared to MIF-stimulated cells in the absence of inhibitor.
Phospho-AKT levels were measured 10 min post-stimulation.
Fig. 4c and d demonstrates that AMD3100 blocked this MIF signal-
ing process. Densitometric scanning of the phospho-AKT to actin
ratio showed a signiﬁcant decrease in MIF-dependent AKT phos-
phorylation due to AMD3100. Similarly, both anti-CXCR4 and
anti-CD74 inhibited MIF-stimulated AKT signaling. In contrast,
only anti-CXCR4 markedly blocked AKT phosphorylation induced
by SDF-1a (Fig. 4e and f). Together, this conﬁrmed that MIF- but
not SDF-1a-induced AKT signaling is mediated by CD74/CXCR4
complexes.4. Discussion
MIF is an inﬂammatory cytokine [1] with chemokine-like
properties [5,6,25]. The receptor mechanism(s) by which MIF acti-
vates target cells have long been unclear. Today it is known that,
dependent on the target cell and inﬂammatory context, MIF can
engage three receptors: (i) CD74, the membrane form of MHC
class II invariant chain [16], (ii) CXCR2, the cognate receptor for
ELR+ CXC chemokines such as CXCL8 [5], and (iii) CXCR4, the cog-
nate receptor for SDF-1a/CXCL12 [5]. Through interaction with
CD74, MIF stimulates ERK1/2 and AKT signaling, regulating cell
proliferation and survival [16,20,24,26]. The MIF/CXCR2 and
MIF/CXCR4 ligand/receptor axes are critical for atherogenic
monocyte/neutrophil and T cell recruitment, respectively, and in-
volve activation of Gi protein-, PI3K-, calcium- and integrin-med-
iated signaling [4,5,25,27]. Antibody blockade experiments in
atherogenic arteries revealed that atherogenic leukocyte recruit-
ment by MIF is dependent on CD74 and an overlap/cross-talk be-
tween the MIF/CD74 and MIF/CXCR2 or MIF/CXCR4 signaling
pathways has been suggested [5]. Receptor binding studies
showed that MIF can individually bind to CD74 or CXCR2/CXCR4
with high afﬁnity independent of whether the other receptor type
was coexpressed; yet coexpression of CD74 with CXCR2 or CXCR4
as it occurs on monocytes ampliﬁes MIF-triggered responses [5].
Thus, it has been proposed that functional heteromeric CD74/
CXCR receptor complexes can form. In fact, following overexpres-
sion of CD74 and CXCR2 or under semi-endogenous expression
conditions, heteromeric CXCR2/CD74 receptor complexes have
been demonstrated [5].
Here we asked whether CXCR4/CD74 receptor complexes exist
and are responsive to MIF. We provide evidence that portions of
CXCR4 and CD74 can form a complex under overexpression con-
ditions, and, importantly under endogenous conditions in mono-
cytes and T cells. Moreover, our study suggests that CXCR4/
CD74 complexes are responsive to MIF, as MIF-triggered CD74-
dependent AKT activation in T cells was blocked by AMD3100, a
small molecule inhibitor of CXCR4, as well as by CD74 and CXCR4
antibodies.
Both CD74 and CXCR4 form homomeric oligomers. The oligo-
meric species of CD74/Ii thought to interact with MHC class II
2756 V. Schwartz et al. / FEBS Letters 583 (2009) 2749–2757during endoplasmic reticulum/Golgi/endolysosomal passage is a
CD74/Ii trimer. It is unknown whether CD74 trimers occur on the
cell surface, although plasma membrane appearance of nonameric
MHC II/Ii complexes in combination with high surface turnover has
been suggested to contribute to endosomal targeting of MHC II/Ii
complexes [18,28–31]. In situations of relative Ii abundance over
class II molecules in the Golgi/endolysosomal compartment, excess
Ii molecules travel to the plasma membrane. Also, CD74 can be
transported to the plasma membrane in the absence of class II
[18]. CXCR4, like CXCR2, has been found to form dimeric com-
plexes, and higher order oligomers have been observed under cer-
tain local or inﬂammatory conditions [32]. Here we demonstrate
that portions of CXCR4 and CD74 can form heteromeric receptor
complexes.
Although unusual, interactions between the chemokine/GPCR
system and single-pass receptors are not unprecedented. In addi-
tion to the CD74/CXCR2 interaction, numerous reports have sug-
gested signaling cross-talk between GPCRs and receptor tyrosine
kinases (RTK) [33,34]. Cross-talk between CXCR4 and an RTK also
has been observed [35]. Of note, it was demonstrated that CD74 di-
rectly interacts with angiotensin II type I receptor (AGTR1), a typ-
ical GPCR [36]. Interestingly, the binding site for CD74 on AGTR1 in
localized in the carboxy-terminal tail, a site identiﬁed as important
for the exit of AGTR1 from the ER and conserved in many GPCRs
[36].
Overall, there has been scarce knowledge about the potential
different functions of oligomeric CXCR chemokine receptor species.
The same is true for CCR chemokine receptors for which several
oligomeric species have been detected [32]. Thus, our study adds
to an understanding of the functionality of homo- and heteromeric
chemokine receptor oligomerization.
Identiﬁcation of the CD74/CXCR4 interaction adds new protein
entities to the limited number of proteins known to bind to CD74
or CXCR4. So far, HLA-DR, CD44, AGTR1, and MIF have been shown
to bind to CD74 [16,29,36,37]. The current list of protein interac-
tion partners for CXCR4 is also limited. In addition to CXCL12
[38,39] and MIF [5,12], only HIV gp120 was found to bind to CXCR4
[38].
CD74 interacts with CD44 and CD44 participates in mediating
MIF signaling [20,37]. In fact, CD44 has been considered a signal-
transducing co-receptor for CD74 [20]. Based on the interaction be-
tween CXCR4 and CD74, it will be important to study if CXCR4/
CD74 complexes comprise CD44 or whether CD44 can be recruited
to such complexes [20,24]. Along this notion, it is intriguing to
speculate about heterotrimeric CXCR2/CD74/CXCR4 or heterotet-
rameric CXCR2/CD74/CXCR4/CD44 complexes. It remains un-
known whether CXCR4/CD74 complexes exist preformed or
whether they inducibly form upon ligand activation. Another unre-
solved question is whether CXCL12/SDF-1a interacts with CXCR4/
CD74 complexes. Our AKT experiments, in which CXCL12-stimu-
lated AKT phosphorylation was inhibited by anti-CXCR4 but hardly
by anti-CD74 argue against this possibility. Hints towards a func-
tional interaction between CD74 and CXCR4 have been obtained
before. For example, Marsh and coworkers observed coexpression
of CD74 and CXCR4 in type II alveolar epithelial cells, but did not
test for direct functional interactions [40].
The functional implications of the herein identiﬁed CD74/
CXCR4 interaction might be important. However, given that only
a portion of CD74 is expressed on the cell surface of most Ii/class
II-positive cells and that chemokine receptor expression such as
that of CXCR4 is intracellular to an appreciable percentage, it
should be emphasized that functional surface-expressed CD74/
CXCR4 complexes may only represent a smaller portion of the
CD74 and CXCR4 pools expressed in a given cell. Yet, such distribu-
tion might change under inﬂammatory situations in favour of the
surface-expressed pool.CD74 mediates several critical activities of the inﬂammatory
cytokine MIF. Similarly, the CXCL12/CXCR4 axis controls key pro-
cesses such as T cell trafﬁcking in inﬂammation and immunity
[7,9,41], tumor cell invasion, metastasis [42], and stem cell homing
[43]. MIF shares with CXCL12 some of its activities [5]. On the
other hand, MIF and CXCL12 exhibit distinct activity proﬁles, at
least in atherogenic T cell recruitment and atheroma progression
[5]. Thus, in addition to the biochemical challenge of unraveling
the molecular details of CD74/CXCR4 complex formation and stoi-
chiometry, CD74/CXCR4 complexes may turn out to be important
for the speciﬁcation of MIF versus CXCL12 actions.
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